Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

Inclusion Criteria: * 1\. Subjects have a height less than two standard deviations (SD) below the median height for individuals of he same age or height,the growth velocity (CV≤4.0 cm/yr),GH peak concentration \<7.0ng/ml in two difference provocative tests, Bone age (BA) ≤9 years in girls and ≤10 years in boys, at least 2 year less than his/her chronological age (CA) * be in preadolescence (Tanner stage 1) and have a CA \> 3 years * have a height value recorded 3 months before the start of GH treatment to calculate pre-treatment GV. * receive no prior GH treatment. * sign informed consent Exclusion Criteria: * 1\. patients positive for hepatitis B e-antibody (HBeAb), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) * 2.Known hypersensitivity to Somatropin or any other components of the study product. * 3\. severe cardiopulmonary or hematological diseases, a current or past history of malignant tumors, immunodeficiency diseases, or mental diseases * 4\. with other growth disorders, such as Turner syndrome, constitutional delay of growth and puberty, and Laron syndrome * 5\. Subjects took part in other clinical trial study during 3 months. * 6\. Other conditions which in the opinion of the investigator preclude enrollment into the study.